Could a common drug prevent brain damage after a stroke?

NCT ID NCT07249853

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug cilostazol can prevent delayed brain injury in people who have had a bleeding stroke from a burst aneurysm. About 316 adults will receive either cilostazol or a placebo for 14 days. The goal is to see if the drug reduces the risk of delayed brain damage and improves long-term recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cilostazol
What this could lead to
If it works, this could provide a new way to prevent delayed brain damage after a bleeding stroke, improving recovery.
What could go wrong
This is a phase 3 trial, but results are not yet available. The drug may not reduce complications or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.